Dinesh Vannan

Dinesh Vannan currently serves as the Lead of Americas for the LSD Franchise at Chiesi Group, overseeing the delivery of over $75 million in revenue for 2024 and managing a budget of $10 million. Vannan has led successful FDA approvals and launches for Lamzede and Elfabrio during the tenure at Chiesi USA, Inc., where the role included responsibilities as Head of US Marketing for the LSD Portfolio. Vannan has held various significant positions in marketing and strategic leadership across organizations such as Intarcia Therapeutics, McCann Health, and ghg | greyhealth group, focusing primarily on rare diseases, diabetes, and cardiovascular health. Vannan’s educational background includes a B.S. in Biology with a focus on Neuroscience from Boston College.